Results 121 to 130 of about 3,663 (172)
Some of the next articles are maybe not open access.
Alirocumab: First Global Approval
Drugs, 2015Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require ...
openaire +2 more sources
Alirocumab: targeting PCSK9 to treat hypercholesterolemia
Drugs of Today, 2015Lowering of low-density lipoprotein (LDL) cholesterol reduces coronary heart disease morbidity and mortality, not only in secondary but also in primary prevention. Statins are generally accepted as a treatment of choice for this. However, still many high-risk and very-high-risk patients fail to achieve target LDL cholesterol values.
I, Pećin, Ž, Reiner
openaire +2 more sources
An evaluation of alirocumab for the treatment of hypercholesterolemia
Expert Review of Cardiovascular Therapy, 2015Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in lipoprotein metabolism, mainly by modulating LDL receptor activity. Alirocumab is a fully human IgG1 monoclonal antibody that binds PCSK9, increases the number of LDL receptors and decreases the levels of LDL cholesterol.
openaire +2 more sources
Alirocumab: Pediatric First Approval
Pediatric DrugsAlirocumab (Praluent®), a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor that has been co-developed by Regeneron Pharmaceuticals, Inc. and Sanofi (formerly sanofi-aventis), is approved globally for use in adults with established cardiovascular disease, primary hyperlipidemia [including heterozygous familial hypercholesterolemia (HeFH ...
openaire +2 more sources